Pharmaceutical Industry Fellowships Program

As a global leader in diabetes care, Abbott is constantly working to deliver the highest quality products and unwavering support to our customers. Consistent and accurate glucose monitoring is the foundation of any diabetes management plan so we’re committed to continuous improvement in the way patients and professionals measure, track and analyze glucose levels. Our science-driven products empower people living with diabetes. Through our innovative product development program, Abbott has developed many cutting-edge glucose monitoring technologies.

In 2015, Alnylam Pharmaceuticals partnered with Northeastern University to offer a unique fellowship opportunity in the heart of Boston. The program set out to equip postdoctoral PharmDs with the skills necessary to develop the advanced medicines of the future, like RNAi. The goal was and remains the same: to cultivate the future leaders of biotechnology and allow fellows to pioneer new therapies for patients. Alnylam fellows are grounded in their core expertise area but utilize the fellowship’s flexibility to branch out and discover other opportunities throughout the organization with personalized rotations. Part of the backbone of the fellowship program is the Northeastern University teaching opportunities which allow fellows to share their knowledge in an educational setting.

The mission at Apellis is to boldly deliver revolutionary therapies for people living with serious diseases by harnessing complement, the foundational part of the human immune system. Vision: A leader in the biotech industry known for compassion, revolutionary science, and contributions to humankind around the world. Apellis is committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting C3.

Founded in 2013, Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. For people living with cancers and other difficult-to-treat diseases, our approach has the potential to be transformative. Our proprietary PROTAC®
protein degraders, or PROteolysis TArgeting Chimeras, work by harnessing the body’s own natural protein disposal system to degrade and remove disease-causing proteins.

At Arvinas, we take our work very seriously, but we also ensure we’re having fun while doing it. We embrace the freedom to pursue innovation, think creatively, and give back. We care about each other, celebrate our accomplishments, and rise up to encourage our colleagues through challenges. Our headquarters is based in New Haven, CT, with approximately 40% of our staff working with virtual or hybrid arrangements nationwide.

Bausch Health Companies Inc. is a global, diversified pharmaceutical company whose mission is to improve people’s lives with our pharmaceutical products. We develop, manufacture and market a range of products primarily in gastroenterology, neurology, dermatology and international pharmaceuticals. With our leading durable brands, we are delivering on our commitments to patients, health care providers, other stakeholders and society as we build an innovative company dedicated to advancing global health. With a robust number of business units such as Ortho Dermatologics and Salix Pharmaceuticals under our umbrella company of Bausch Health, our Fellows are exposed to various therapeutic landscapes throughout their two-year program.

Blueprint Medicines is a global precision therapy company striving to improve human health. With a focus on genomically defined cancers, rare diseases and cancer immunotherapy, we combine our leading expertise in protein kinases with a uniquely targeted, scalable approach to empower the rapid design and development of transformational medicines.

In collaboration with Northeastern University, Blueprint Medicines offers two-year PharmD fellowships in the following specialties. Apply today!

Braeburn is dedicated to delivering solutions for people living with the serious consequences of opioid use disorder. At Braeburn, we challenge the status quo and champion transformation of the
management of opioid use disorder (OUD) by partnering with the community to create a world where every person with OUD gets the best possible care and opportunity to reach their full potential.

We believe that together we will transform the management of OUD. At Braeburn, we know that our greatest strength is our people whose diverse perspectives shape our purpose, culture, and values. It’s important to us that we create equity in the workplace and recovery community. We are just beginning, and we will continue to strive for greatness by:

• Cultivating a high-performing culture and workforce that exhibit the values of diversity, equity, inclusion
  and belonging
• Encouraging safe spaces for diverse perspectives to be heard and influence what we do
• Being bold in our initiatives to reduce stigma and discrimination and improve health equity
• Addressing the challenges that diverse groups face and ensure equitable access to care

BridgeBio Pharma Inc. (BridgeBio) is a biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers, and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible.

BridgeBio exists to bring meaningful medicines to patients as quickly and as safely as possible. We’re passionate about fostering open and transparent relationships with patients and their families by staying connected, listening to their experiences, and applying their insights into our work. We hope that by developing these relationships with patients, families, and patient advocacy organizations early in the development phase of our therapies that we can also craft our clinical trial protocols with the patient experience at the forefront.

About Eidos Therapeutics, Inc. a BridgeBio Company

Transthyretin (TTR) amyloidosis (ATTR) is a rare, underdiagnosed, and life-threatening disease with limited treatment options that can damage the heart and/or nervous system. BridgeBio’s mission is to improve the morbidity and mortality of patients with ATTR through the discovery and development of a novel therapeutic through its affiliate, Eidos Therapeutics.

Patients are the beginning and the end of our journey. Through passion, courage, teamwork and innovation, we seek to revolutionize the lives of patients living with rare diseases by providing an integrated set of definitive solutions. We commit to offer patients, and those who take care of them, innovative solutions in the management of their needs, exploring new frontiers in treatment and care. We work in close partnership with patients, caregivers, patients associations, healthcare practitioners, regulatory and pricing authorities.

Chiesi Global Rare Diseases is a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases. As a family business, Chiesi Group strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet.

Seqirus is part of CSL Limited (ASX: CSL). As one of the largest influenza vaccine providers in the world, Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness. With state-of-the-art production facilities in the U.S., the U.K. and Australia, and leading R&D capabilities, Seqirus utilizes egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries around the world.

Influenza kills. But at Seqirus, we believe it shouldn’t be that way. As the only vaccine company with a singular global focus on influenza, we work tirelessly on cutting-edge research, transformative technologies and the latest methods of production and distribution. Together with our partners we’re on the front line every day, protecting communities from seasonal influenza and global pandemic threats.Our vision is a world protected from influenza.

GSK is a global biopharma company with the ambition and purpose to unite science, technology, and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people over the next 10 years. Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.

We prioritize innovation in vaccines and specialty medicines, maximizing the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics and advanced technologies, and our world-leading capabilities in vaccines and medicines development. We will focus on four therapeutic areas: infectious diseases, HIV, oncology, and immunology.

Ipsen is a global, biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neuroscience and Rare Diseases. Our presence in North America dates back to 1976, and now includes Ipsen’s third global hub right in the heart of the leading global biotech ecosystem in Cambridge, Mass., where a fully integrated biopharmaceutical team across External Innovation and Partnering, R&D, Manufacturing and Commercial operations collaborates.

With Ipsen’s expansion of its footprint in Cambridge, and new North America headquarters in Kendall Square, the group is building a sustainable innovation engine within the biotech community.

Ironwood Pharmaceuticals is a patient-focused, biopharmaceutical company on a mission to push the boundaries of the gastrointestinal (GI) field by advancing the treatment of GI diseases and redefining the standard of care for millions of patients.

At Ironwood Pharmaceuticals, we are committed to advancing the treatment of GI diseases and redefining the standard of care for GI patients. As a pioneer and champion in the development of a market-leading therapy for IBS-C and CIC, we are singularly focused on advancing the treatment of GI diseases and continue to challenge what has been done before to shape what the future holds. So, we named ourselves after the Ironwood tree, which can live for thousands of years in the harshest desert, creating a shaded microclimate in which life thrives. Iron, like science, is undeniable and strong. Wood, like artistry and humanity, is flexible, resilient and versatile. The two words together represent our passion for making a positive impact on the health – and lives- of GI patients, their families and communities.

Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer.

Our company was founded in 2008 with a vision of pioneering a potentially new approach to treating patients with cancer and other serious diseases. Our novel approach to cancer treatment involves targeting the export of specific proteins in a cancer cell’s nucleus with SINE technology.

Our primary focus is on developing novel drugs which we hope will help treat patients with certain blood cancers or solid tumor malignancies.

Pacira is the leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving patient outcomes. Our in-depth knowledge of non-opioid pain management, coupled with our passion for delivering improved patient care, drives our commitment to providing solutions that address unmet medical needs and improve clinical results.

We are a team of dedicated and highly talented professionals focused on driving improved patient outcomes with opioid-reducing strategies. We are an organization built on high ethical standards, an unwavering commitment to patients, and transparent communications. We have a drive and a desire to improve the world around us and make a meaningful difference in the lives of patients, families, communities, and society.

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders, or CNS, characterized by neuronal excitation-inhibition imbalance. Praxis is applying insights from genetic epilepsies to both rare and more prevalent neurological disorders, using our understanding of shared biological targets and circuits in the brain.

Trust, Ownership, Curiosity, and Results are foundational in every aspect of our business and are exemplified by each one of our team members. We Dare for More in every aspect of our journey, from the patients we are working for, to the portfolio we build and advance every day, and to ourselves and our relationships.

In collaboration with Northeastern University, Praxis Precision Medicines offers a two-year PharmD fellowship in Medical Affairs

Sarepta is a global biotechnology company on an urgent mission: to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short.

We’re ushering in a new era of drug development with the goal of driving efficiencies, including shortening the time from lab to patient and building the world’s largest gene therapy manufacturing capacity. We’re collaborating with health networks and payers, rethinking pricing models for revolutionary new treatments in development. We are in a daily race to transform genetic understanding into genetic medicine. Because every day is an opportunity to save lives stolen by rare disease.

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of cell and genetic therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Founded in 1989 in Cambridge, Mass., Vertex’s global headquarters is now located in Boston’s Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry’s top places to work, including 11 consecutive years on Science magazine’s Top Employers list and a best place to work for LGBTQ equality by the Human Rights Campaign.